Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$14.52
-6.4%
$12.55
$7.30
$16.32
$721.93M-0.04571,330 shs2.09 million shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$12.57
+1.8%
$8.45
$6.53
$30.60
$109.74M2.75132,158 shs56,671 shs
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$2.69
$2.28
$1.46
$4.10
$17.92M0.1944,175 shs11,204 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$11.03
-0.5%
$8.36
$5.79
$11.78
$1.76B1.431.44 million shs2.13 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-3.00%+30.34%+9.15%+34.99%+23.39%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-0.24%+8.76%+49.52%+4.57%-37.42%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
-2.18%-5.11%+16.96%+43.85%-3.58%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+2.97%+18.38%+24.35%+55.84%+54.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4.1595 of 5 stars
3.61.00.04.43.11.70.6
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.5901 of 5 stars
2.92.00.04.62.80.80.0
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
1.9175 of 5 stars
0.05.00.04.20.00.81.3
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.9212 of 5 stars
3.51.00.04.12.72.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera AG stock logo
BFRA
Biofrontera
0.00
N/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3.11
Buy$26.2981.03% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67486.05% Upside
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.00
HoldN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.00
Buy$17.3357.15% Upside

Current Analyst Ratings Breakdown

Latest OCUL, KALV, BFRA, MCRB, and MEIP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.00
7/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $27.00
7/7/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.00
5/29/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
5/6/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/A$4.86 per shareN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M0.87N/AN/A$1.61 per share7.81
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/A$5.85 per share0.46$4.96 per shareN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$63.72M27.58N/AN/A$2.01 per share5.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$126.64M-$3.72N/AN/AN/AN/A-104.25%-78.69%9/4/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)

Latest OCUL, KALV, BFRA, MCRB, and MEIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.35N/AN/AN/A$13.12 millionN/A
7/10/2025Q4 2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.83-$3.69-$2.86-$0.99$4.20 millionN/A
5/13/2025Q3 2025
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A-$0.39N/A-$0.39N/AN/A
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
10.44
10.44
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A
16.78
16.78
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.26
10.22
10.14

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
52.38%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10049.72 million44.50 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million8.32 millionOptionable
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
1006.66 millionN/AOptionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230159.30 million155.64 millionOptionable

Recent News About These Companies

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

KalVista Pharmaceuticals stock logo

KalVista Pharmaceuticals NASDAQ:KALV

$14.52 -0.99 (-6.38%)
Closing price 04:00 PM Eastern
Extended Trading
$14.24 -0.28 (-1.93%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$12.57 +0.22 (+1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$12.56 -0.02 (-0.12%)
As of 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MEI Pharma stock logo

MEI Pharma NASDAQ:MEIP

$2.69 0.00 (0.00%)
Closing price 03:51 PM Eastern
Extended Trading
$2.65 -0.04 (-1.49%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$11.03 -0.05 (-0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$11.08 +0.04 (+0.41%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.